

//  
//

( )

## BILAG index

\*

(SLE) :

SLE

:

:

(P < / / ± / / ± /

:

**BILAG index** :

SLE

(.)

(SLE)

(.)

SLE

SLE

SLE

Body Mass Index (BMI)

.( )

SLE

.( )

( )

.( )

SLE

SLE

SLE

SLE

International Diabetes Federation (IDF) 2004

.( )

.( )

%

.( )

SLE

cm

)

(

cm

:

.( )

mg/dl

mg/dl

HDL

SLE

mg/dl

.( )

HDL

/

mg/dl

.( )

( Mean ± SD )

(BILAG)

British Isles Lupus Assessment Group Index

/ ± /  
/ ± /  
/ ±     ± /

/ ± /   / ± /

)

(

mg )

/ ± /   / ± /

(

(P < / )

A

NSAID

B

NSAID

C

(P < / )

( ) ESR

( )

E D

( )

(P < /   P < / )

( )

BILAG Index

(P < / )

SPSS

ANOVA

P < /

( )

( )

)  
(

( )  
ESR

ESR

( )

( )

( )

ESR

HDL

SLE

( ) ( )

( ) SLE

( ) SLE

SLE

( )

SLE

INF- $\alpha$  L-1 ) (CRP

( )

SLE

## **REFERENCES**

---

1. Ripen Y, Strauss BJ, Moran EF. Body composition in systemic lupus erythematosus. *Br J Rheumatol* 1998; 37: 514-9.
2. Gehi A, Webb A, Nolte M, Davis J Jr. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with Cyclophosphamide and Mycophenolate mofetil. *Arthritis Rheum* 2003; 48: 1070-67.
3. Kipen Y, Briganti EM, Strauss BJ, Littlejohn GO, Morand EF. Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. *Rheumatology (Oxford)* 1999; 38: 59-65.
4. Tso TK, Huang HY, Chang CK, Liao YJ, Huang WN. Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. *Clin Rheumatol* 2004; 23: 416-20.
5. Oeser A, Chung CP, Asanuma Y. Obesity in an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. *Arthritis Rheum* 2005; 11: 3651-9.
6. Bernatsky S, Boivin JF, Joseph L. Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues and obesity. *J Rheumatol* 2002; 29: 2551-4.

7. Petri M. Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus cohort. *Lupus* 2000; 9: 170-5.
8. Gregg EW, Cheng YJ, Cadwell BL. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. *J Am Med Assoc* 2005; 293: 1868-74.
9. Ryan MJ, McLemore GR, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. *Hypertension* 2006; 48: 988-93.
10. El-Magadmi M, Ahmad Y, Turkic W. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. *J Rheumatol* 2006; 33(1): 50-6.
11. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. *J Immunol* 1989; 143: 3470-5.
12. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. *J Clin Invest* 1994; 94: 585-91.
13. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin 6-exacerbates glomerulonephritis in (NZB NZW) F1 mice. *Am J Pathol* 1994; 144: 927-37.
14. Chung CP, Oeser A, Solus J. Inflammatory mechanisms affecting the lipid profile in patients with Systemic Lupus Erythematosus. *J Rheumatol* 2007; 34: 1849-54.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25(11): 1271-7.
16. Saely CH, Koch L, Schmid F, Marte T, Aczel S. Adult treatment 16, panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. *Diabetes Care* 2006; 29(4): 901-7.
17. Gordon C, Sutcliffe N. Definition and treatment of lupus flares measured by the BILAG index. *Rheumatology* 2003; 42: 1372-9.
18. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy; A study of 36 necropsy patients. *Am J Med* 1975; 58: 243-64.
19. Roman MJ, Shanker BA, Davis A. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Eng J Med* 2003; 349: 2399-406.
20. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. *Ann Rheum Dis* 2007; 66: 208-214.
21. Laing I, Yates AP, Owen DC. Beta cell function and insulin sensitivity in polycystic ovary syndrome (PCOS) and newly diagnosed type 2 diabetics. *Proc ACB National Meeting* 2001; 79: 54.
22. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in proinflammatory state. *Circulation* 2004; 110: 1564-71.

- 
23. Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. *Clin Exp Rheumatol* 2004; 18: 565-70.
  24. Aringer M, Smolen JS. Tumor necrosis factor and other pro-inflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic interventions. *Lupus* 2004; 13: 344-7.